Thiostrepton Drug Asset Due Diligence Report 2026

This Thiostrepton Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Thiostrepton can convert its Synthetic peptide, Cyclic Peptide profile and 50S subunit x FOXM1 x PRDX3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Thiostrepton (query alias: Thiostrepton)
Modality / target	Synthetic peptide, Cyclic Peptide; 50S subunit x FOXM1 x PRDX3; 50S subunit inhibitors, FOXM1 inhibitors, PRDX3 inhibitors
Highest global status	Phase 2
Originator	RS Oncology LLC
Active developers	RS Oncology LLC, Shin Kong Wu Ho-Su Memorial Hospital, University of Leicester

The MCP disease footprint includes Metastatic breast cancer, Non-Small Cell Lung Cancer, Ovarian Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
No matched detailed trial record returned.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Thiostrepton addresses Metastatic breast cancer, Non-Small Cell Lung Cancer, Ovarian Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: 50S subunit x FOXM1 x PRDX3 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2021-12-02	成都金瑞基业生物科技有限公司宣布与美国西北大学就JRF101新用途研究达成协议	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Administration of low-dose thiostrepton for treating cancer”. The milestone feed surfaced a patent-application signal described as “Thiostrepton therapies, dosing regimens, patient populations, and combination therapies”. The milestone feed surfaced a patent-application signal described as “Thiostrepton dosing regimens”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION